Tag: US03168L1052

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte^®. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third quarter of 2025.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsUS03168L1052

Aker ASA: Presentation of Second-Quarter and Half-Year Results 2025

US $1,000 quick loan No Credit Check Loans: Radcred Launches Instant Bad Credit Loans For Emergency Need

Compagnie de l’Odet : DECLARATION AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L’AUTORITE DES MARCHES FINANCIERS

Tag: US03168L1052

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us